Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. WYFI
6. STUB
7. EAT
8. NVDA
9. GO
10. ARX

Go back to Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. (NASDAQ: NVAX) Delayed: 8.21 +0.25 (3.14%)
Previous Close $7.96    52 Week High $9.23 
Open $8.01    52 Week Low $1.16 
Day High $8.23    P/E N/A 
Day Low $7.92    EPS $-0.30 
Volume 2,032,464       

Novavax, Inc. (NASDAQ: NVAX) Delayed: 8.21 +0.25 (3.14%)
Previous Close $7.96    52 Week High $9.23 
Open $8.01    52 Week Low $1.16 
Day High $8.23    P/E N/A 
Day Low $7.92    EPS $-0.30 
Volume 2,032,464